General

  • Target
    https://metrics.thebiotechstartupspodcast.co/gh/c/v2.k1.ofw54lgyq1t2jL4nyBcU0R-sywxZfHfluYkB012xbNBKLu4fSN8eFswK7M_lGkTzGtWagNolffHctkv4A-Y6nnSc39T3F1hiGZ2qg8cCM-VoxIL3Sm8EbM6jHZJ-UrAb6UM2GJyr9se83AqWmhROX3EBsJi4dJ7vDmlVWd2U32aD9CnsAyGoKQUa7gocU1GuTa-Km4k6wH8pl3LEzfkv1pm0gR0Ugc24G-taL7p5yRjL72-I_KUSwOwj0Ilc1_WmdW5XEWFXUjqdK2Z64s2tgh3mUrLpgtMgpxrOnfzsGTSlioQx3WWov0Z4OzqvPGU-1dEBEyRgcX_7UvqP4AzS1XPpU6RIcRsEQ9hnZAzW91wjcUTacZuwASPTH5glci1_cYvt8dy0OMpQXuYtUB4RytdULabYbPjeNEwsLne_zRkozNME8GGTkR_KKA5hcwM
  • Sample261027-ey1vcsav4v
Score
3/10

Malware Config

Targets

    • Target
      https://metrics.thebiotechstartupspodcast.co/gh/c/v2.k1.ofw54lgyq1t2jL4nyBcU0R-sywxZfHfluYkB012xbNBKLu4fSN8eFswK7M_lGkTzGtWagNolffHctkv4A-Y6nnSc39T3F1hiGZ2qg8cCM-VoxIL3Sm8EbM6jHZJ-UrAb6UM2GJyr9se83AqWmhROX3EBsJi4dJ7vDmlVWd2U32aD9CnsAyGoKQUa7gocU1GuTa-Km4k6wH8pl3LEzfkv1pm0gR0Ugc24G-taL7p5yRjL72-I_KUSwOwj0Ilc1_WmdW5XEWFXUjqdK2Z64s2tgh3mUrLpgtMgpxrOnfzsGTSlioQx3WWov0Z4OzqvPGU-1dEBEyRgcX_7UvqP4AzS1XPpU6RIcRsEQ9hnZAzW91wjcUTacZuwASPTH5glci1_cYvt8dy0OMpQXuYtUB4RytdULabYbPjeNEwsLne_zRkozNME8GGTkR_KKA5hcwM
    Score
    3/10

MITRE ATT&CK Enterprise v16

Tasks